![Monica M. Siegenthaler](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Monica M. Siegenthaler
Hoofd Techniek/Wetenschap/O&O bij NeoStem Oncology LLC
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Mark Surfas | M | - |
NeoStem Oncology LLC
![]() NeoStem Oncology LLC Pharmaceuticals: MajorHealth Technology NeoStem Oncology LLC is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. Founded in 2005, the mission of NeoStem Oncology is to catalyze the efficient development of human therapies based on human embryonic stem cells. The key to this goal is the production and supply of clinically relevant human cell populations using a scalable, efficient and highly reproducible process. They generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes that are FDA compliant from day one. And they do this at a fraction of the cost of conventional cell manufacturing. As a result, the company can economically supply large quantities of high purity cells for its own clinical development pipeline in specific application areas. It can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research. NeoStem Oncology LLC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA. | 19 jaar |
David A. Frosh | M | 65 |
NeoStem Oncology LLC
![]() NeoStem Oncology LLC Pharmaceuticals: MajorHealth Technology NeoStem Oncology LLC is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. Founded in 2005, the mission of NeoStem Oncology is to catalyze the efficient development of human therapies based on human embryonic stem cells. The key to this goal is the production and supply of clinically relevant human cell populations using a scalable, efficient and highly reproducible process. They generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes that are FDA compliant from day one. And they do this at a fraction of the cost of conventional cell manufacturing. As a result, the company can economically supply large quantities of high purity cells for its own clinical development pipeline in specific application areas. It can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research. NeoStem Oncology LLC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA. | - |
Jason Livingston | M | 53 |
NeoStem Oncology LLC
![]() NeoStem Oncology LLC Pharmaceuticals: MajorHealth Technology NeoStem Oncology LLC is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. Founded in 2005, the mission of NeoStem Oncology is to catalyze the efficient development of human therapies based on human embryonic stem cells. The key to this goal is the production and supply of clinically relevant human cell populations using a scalable, efficient and highly reproducible process. They generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes that are FDA compliant from day one. And they do this at a fraction of the cost of conventional cell manufacturing. As a result, the company can economically supply large quantities of high purity cells for its own clinical development pipeline in specific application areas. It can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research. NeoStem Oncology LLC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA. | - |
Gregory Bonfiglio | M | 72 |
NeoStem Oncology LLC
![]() NeoStem Oncology LLC Pharmaceuticals: MajorHealth Technology NeoStem Oncology LLC is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. Founded in 2005, the mission of NeoStem Oncology is to catalyze the efficient development of human therapies based on human embryonic stem cells. The key to this goal is the production and supply of clinically relevant human cell populations using a scalable, efficient and highly reproducible process. They generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes that are FDA compliant from day one. And they do this at a fraction of the cost of conventional cell manufacturing. As a result, the company can economically supply large quantities of high purity cells for its own clinical development pipeline in specific application areas. It can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research. NeoStem Oncology LLC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA. | 12 jaar |
Mercy Udoh | F | - |
NeoStem Oncology LLC
![]() NeoStem Oncology LLC Pharmaceuticals: MajorHealth Technology NeoStem Oncology LLC is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. Founded in 2005, the mission of NeoStem Oncology is to catalyze the efficient development of human therapies based on human embryonic stem cells. The key to this goal is the production and supply of clinically relevant human cell populations using a scalable, efficient and highly reproducible process. They generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes that are FDA compliant from day one. And they do this at a fraction of the cost of conventional cell manufacturing. As a result, the company can economically supply large quantities of high purity cells for its own clinical development pipeline in specific application areas. It can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research. NeoStem Oncology LLC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA. | - |
Aleksandra J. Poole | M | - |
NeoStem Oncology LLC
![]() NeoStem Oncology LLC Pharmaceuticals: MajorHealth Technology NeoStem Oncology LLC is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. Founded in 2005, the mission of NeoStem Oncology is to catalyze the efficient development of human therapies based on human embryonic stem cells. The key to this goal is the production and supply of clinically relevant human cell populations using a scalable, efficient and highly reproducible process. They generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes that are FDA compliant from day one. And they do this at a fraction of the cost of conventional cell manufacturing. As a result, the company can economically supply large quantities of high purity cells for its own clinical development pipeline in specific application areas. It can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research. NeoStem Oncology LLC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA. | - |
Craig T. Fredrickson | M | - |
NeoStem Oncology LLC
![]() NeoStem Oncology LLC Pharmaceuticals: MajorHealth Technology NeoStem Oncology LLC is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. Founded in 2005, the mission of NeoStem Oncology is to catalyze the efficient development of human therapies based on human embryonic stem cells. The key to this goal is the production and supply of clinically relevant human cell populations using a scalable, efficient and highly reproducible process. They generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes that are FDA compliant from day one. And they do this at a fraction of the cost of conventional cell manufacturing. As a result, the company can economically supply large quantities of high purity cells for its own clinical development pipeline in specific application areas. It can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research. NeoStem Oncology LLC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA. | - |
Kenneth L. Berger | M | - |
NeoStem Oncology LLC
![]() NeoStem Oncology LLC Pharmaceuticals: MajorHealth Technology NeoStem Oncology LLC is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. Founded in 2005, the mission of NeoStem Oncology is to catalyze the efficient development of human therapies based on human embryonic stem cells. The key to this goal is the production and supply of clinically relevant human cell populations using a scalable, efficient and highly reproducible process. They generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes that are FDA compliant from day one. And they do this at a fraction of the cost of conventional cell manufacturing. As a result, the company can economically supply large quantities of high purity cells for its own clinical development pipeline in specific application areas. It can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research. NeoStem Oncology LLC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA. | - |
Gabriel I. Nistor | M | - |
NeoStem Oncology LLC
![]() NeoStem Oncology LLC Pharmaceuticals: MajorHealth Technology NeoStem Oncology LLC is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. Founded in 2005, the mission of NeoStem Oncology is to catalyze the efficient development of human therapies based on human embryonic stem cells. The key to this goal is the production and supply of clinically relevant human cell populations using a scalable, efficient and highly reproducible process. They generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes that are FDA compliant from day one. And they do this at a fraction of the cost of conventional cell manufacturing. As a result, the company can economically supply large quantities of high purity cells for its own clinical development pipeline in specific application areas. It can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research. NeoStem Oncology LLC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 9 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Monica M. Siegenthaler
- Persoonlijk netwerk